Form 6-K NOVARTIS AG For: Dec 31
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
Report on Form 6-K dated February 4, 2026
(Commission File No. 1-15024)
Novartis AG
(Name of Registrant)
Lichtstrasse 35
4056 Basel
Switzerland
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F:
|
Form 20-F: ☒
|
Form 40-F: ☐
|
Exhibits:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Novartis AG
|
|||
|
Date: February 4, 2026
|
By:
|
/s/ PAUL PENEPENT
|
|
|
Name:
|
Paul Penepent
|
||
|
Title:
|
Head Financial Reporting and Accounting
|
||
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Luxxfolio Announces Closing of Oversubscribed Non-Brokered Private Placement
- ENERGIZER HOLDINGS, INC. TO WEBCAST A DISCUSSION OF THIRD QUARTER FISCAL YEAR 2026 RESULTS ON AUGUST 4
- Bitcoin Price Prediction: $70K Breakout Could Revive Bitcoin as AlphaPepe Offers Retail x150 Potential Before Launch
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
